Moleculin CEO to Present at Webull Financial Virtual Conference
Event summary
- Moleculin Biotech to present at Webull Financial's Corporate Connect Webinar Series on February 11, 2026, at 1:20 PM EST.
- CEO Walter Klemp will lead the presentation.
- Webull Financial serves tens of millions of users globally.
- Moleculin's lead program, Annamycin, is in Phase 3 trials for AML and STS lung metastases.
The big picture
Moleculin's participation in Webull's virtual conference underscores the growing trend of biotech firms engaging directly with retail investors through digital platforms. The event comes as Moleculin advances its lead drug, Annamycin, through pivotal trials, positioning it among a cohort of small-cap biotechs with high-risk, high-reward clinical pipelines. The strategic use of investor conferences may help Moleculin navigate market volatility as it seeks to de-risk its development pathway.
What we're watching
- Clinical Progress
- The pace at which Moleculin advances its Phase 3 MIRACLE trial for Annamycin will determine its near-term valuation.
- Investor Engagement
- Whether Moleculin can leverage Webull's platform to attract new institutional or retail investors.
- Pipeline Development
- How Moleculin balances its focus between Annamycin and other pipeline candidates like WP1066 and WP1122.